Stay updated on Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial
Sign up to get notified when there's something new on the Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial page.

Latest updates to the Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial page
- Check2 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2, and the 'Back to Top' element was removed; no other substantive changes to core content, pricing, or time-slot information are present.SummaryDifference0.2%
- Check9 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%
- Check17 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as detailed medical terms related to leukemia and various compounds, while removing several location-related terms and some medical classifications.SummaryDifference4%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has updated its version from v2.16.11 to v2.16.12 and has removed older dates from May and June 2025, replacing them with new dates in August 2025.SummaryDifference0.6%
- Check38 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check45 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference1.0%
Stay in the know with updates to Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial page.